Breo Ellipta (fluticasone furoate/vilanterol) Inhalation Powder

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) February 2016 ADVERSE REACTIONS Post-Marketing Experience Musculoskeletal and Connective Tissue Disorders Muscle Spasms ...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts